Exeliom Biosciences: a new generation of microbiota-derived biotherapies
… a specific bacterium, Faecalibacterium prausnitzii (Fprau), was consistently absent in patients experiencing a relapse … of patients treated with immunotherapy. A lean biotech model for oncology Exeliom Biosciences operates as a lean … makes it possible to deliver a precise dose in gastro-resistant capsule form and marks the achievement of an industrial …
Published on: